Skip to main content
Premium Trial:

Request an Annual Quote

Takeda Adopts Definiens Biomarker Analysis Platform

NEW YORK (GenomeWeb) – Definiens announced today that Takeda Pharmaceuticals will use its new cloud-based digital pathology platform in its translational and biomarker research.

When combined with deeply researched biomarker analysis, Definiens said its new platform, VeriTrova, can help translate biomarker research into the clinic through a new generation of diagnostics. Takeda, an early adopter of the platform, plans to use it for comprehensive tissue-based analysis in its clinical trials, and to support its clinical biomarker development programs.

"VeriTrova accelerates clinical trials through remote uploading and viewing of digitized [immunohistochemistry] images from wet-lab partners and CROs to the cloud, where the images are analyzed," Thomas Colarusso, vice president of business development and strategy at Definiens, said in a statement.

Andrew Dorner, Takeda's vice president and global head of translational medicine, added that Definiens' system "will improve the timelines and quality of our image analysis for clinical biomarkers." 

Definiens said the real-time analysis provided by VeriTrova can help Takeda reduce normal processes from months to weeks, and can provide more automated and standardized image analysis readouts.